Search
Research
The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of MethodologyOur review highlights similarities and differences in the application of the test-negative design that deserve further examination
Research
Associations between ethnicity, social contact, and pneumococcal carriage three years post-PCV10 in FijiIndigenous iTaukei had greater frequency and intensity of contact compared with Fijians of Indian Descent
Research
S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccineBased on descriptive analyses of this small study, S. aureus 3-antigen vaccine vaccination did not impact S. aureus acquisition or carriage
Research
Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveysDirect and indirect effects on pneumococcal carriage post-PCV10 are likely to result in reductions in pneumococcal disease, including in infants too young to be vaccinated
Research
Comprehensive candidate gene analysis for symptomatic or asymptomatic outcomes of Leishmania infantum infection in BrazilOur results imply a role for IgG-mediated inflammation in determining delayed-type hypersensitivity associated with asymptomatic leishmaniasis
Research
Characterizing the risk of respiratory syncytial virus in infants with older siblings: a population-based birth cohort studyOur results lend support to a vaccination strategy which includes family members in order to provide maximum protection for newborn babies.
Research
Targeting the mucosal immune system in a mouse model to prevent pregnancy complications following maternal bacterial infectionThis work is the first step to develop safe treatments for pregnant mums to protect against preterm delivery and low birth weight caused by maternal infections.
Research
Predominance of nontypeable haemophilus influenzae in children with otitis mediaIn Australia the 7-valent pneumococcal conjugate vaccine (PCV7) is administered at 2, 4 and 6 months of age, with no booster dose.
Research
Innate immunity in human newborn infants: prematurity means more than immaturityNeonates, particularly those born prematurely, are exquisitely vulnerable to life-threatening infections. This increased susceptibility to infection...
Research
TLR1/2 activation during Heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T cell responses providingLeishmania (Viannia) parasites present particular challenges, as human and murine immune responses to infection are distinct from other Leishmania species